The Pharma Data

NOVEMBER 9, 2020

Image: Copyright © 2009-2020 Merck Sharp & Dohme Corp., The product is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight off tumor cells. a subsidiary of Merck & Co., Kenilworth, N.J., All rights reserved. Merck , also known as MSD outside of the U.S. Source link.

Research Laboratories 52

Research Laboratories Laboratories Treatment Therapies 52

Drug Target Review

SEPTEMBER 26, 2023

Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. 2009 Sep;14(17–18):876–84.

Drugs 111

Drugs FDA Disease Animal Testing 111

The Pharma Data

NOVEMBER 17, 2020

In 2009 Tony took on the challenge of a new start up in San Antonio at RMATX that has grown to 2 IVF centers and 2 satellite centers. Dr. Cooper has authored articles for several medical journals and textbooks, led clinical studies, and has had her research covered in the local and national press.

Laboratories 52

Laboratories Nurses Doctors International 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

I completed a few long-distance rides and raised some funds for research, and in the process, I realized this is what I wanted to do with the rest of my life. I joined the FARA staff in 2009, and our team built a nationwide series of bike rides called rideATAXIA to raise funds for research.

Disease 52

Disease Clinical Trials Trials Treatment 52

The Pharma Data

NOVEMBER 11, 2020

managing partner and director of clinical research, Sierra Eye Associates, clinical associate professor of ophthalmology, University of Nevada Presentation date and time: The pre-recorded presentation containing slides and audio will be available to AAO 2020 Virtual attendees starting on Wednesday, November 11.

Science 40

Science Treatment Disease Engineering 40

The Pharma Data

JUNE 24, 2021

The prognosis for men with advanced prostate cancer has significantly improved since the introduction of novel hormone therapies, but additional therapeutic options are needed for the approximately 25 percent of men with tumors harboring DNA damage response (DDR) gene mutations, who may have poorer outcomes,” said Chris Boshoff, M.D.,

Clinical Trials 52

Clinical Trials DNA Trials Treatment 52

The Pharma Data

NOVEMBER 8, 2020

The HPTN 084 study, with 3,223 participants in 20 sites across seven countries in sub-Saharan Africa (Botswana, Kenya, Malawi, South Africa, eSwatini, Uganda and Zimbabwe), is the first study of long-acting injectable therapy for HIV prevention among women. For more information, visit hptn.org.

Trials 40

Trials Treatment Science Research 40